Barclays’s MacroGenics MGNX Stock Holding History

Barclays’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,000	Closed	-$21.3K	–	5404
2024 Q2	$21.3K	Buy	+5,000	New	+$48.7K	﹤0.01%	4428

Other funds holding MGNX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Barclays's MGNX Position: Q2 2026 in Review

Barclays reduced its MacroGenics (MGNX) stake by 20% in Q2 2026, selling an estimated $48.4K and leaving 49,830 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #3621.

Barclays first reported a position in MGNX in Q4 2013 and has held it in 50 quarters since. The position peaked at $3.4M in Q1 2021. 122 funds tracked by Wall St. Rank hold MGNX as of Q2 2026.

Barclays held 49,830 shares of MacroGenics worth $230K as of Q2 2026.
Barclays sold 12,797 MacroGenics shares in Q2 2026, an estimated $48.4K.
MacroGenics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3621 holding.
Barclays first reported a position in MacroGenics in Q4 2013 and has held it in 50 quarters since.
Barclays's MacroGenics position peaked at $3.4M in Q1 2021.
122 funds tracked by Wall St. Rank held MacroGenics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.